ArticleMolecular biology of the cell1993
In vitro fusion of endocytic vesicles is inhibited by cyclin A-cdc2 kinase.
Article in Molecular biology of the cell, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- Cyclin A2 localises in the cytoplasm at the S/G2 transition to activate PLK1.Life science alliance · 2021Article
- Clathrin-mediated endocytosis is inhibited during mitosis.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Breaking up is hard to do - membrane traffic in cytokinesis.Journal of cell science · 2008Article
- Centrosome overduplication, increased ploidy and transformation in cells expressing endoplasmic reticulum-associated cyclin A2.Oncogene · 2002Article
- Cleavage of rabaptin-5 blocks endosome fusion during apoptosis.The EMBO journal · 1997Article
- A role for tubular networks and a COP I-independent pathway in the mitotic fragmentation of Golgi stacks in a cell-free system.The Journal of cell biology · 1995Article
- Cyclins and cyclin-dependent kinases: a biochemical view.The Biochemical journal · 1995Review
- Human cyclins B1 and B2 are localized to strikingly different structures: B1 to microtubules, B2 primarily to the Golgi apparatus.The EMBO journal · 1995Article
- Multiple N-ethylmaleimide-sensitive components are required for endosomal vesicle fusion.Molecular biology of the cell · 1994Article
- COP-coated vesicles are involved in the mitotic fragmentation of Golgi stacks in a cell-free system.The Journal of cell biology · 1994Article
- Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein.The EMBO journal · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Receptor-mediated endocytosis and recycling are inhibited in mitotic mammalian cells, and previous studies have shown that inhibition of endocytic vesicle fusion in vitro occurs via cyclin B-cdc2 kinase. To test for the ability of cyclin A-cdc2 kinase to inhibit endocytic vesicle fusion, we employed recombinant cyclin A proteins. Addition of cyclin A to interphase extracts activated a histone kinase and markedly reduced the efficiency of endocytic vesicle fusion. By a number of criteria, inhibition of fusion was shown to be due to the action of cyclin A, via the mitosis-specific cdc2 kinase, and not an indirect effect through cyclin B. Two-stage incubations were used to demonstrate that at least one target of cyclin A-cdc2 kinase is a cytosolic component of the fusion apparatus. Reconstitution experiments showed that this component was also modified in mitotic cytosols and was unaffected by N-ethyl maleimide treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.